Medindia
Medindia LOGIN REGISTER
Advertisement

AbbVie Announces Global Resolution of HUMIRA® (adalimumab) Patent Disputes with Fresenius Kabi

Thursday, October 18, 2018 General News
Advertisement
- Agreements Provide Non-Exclusive License to Fresenius Kabi for HUMIRA-Related Intellectual Property in the U.S. Effective September 30, 2023, and in Other Markets on Different Dates

Sponsored Post and Backlink Submission


Latest Press Release on General News

This site uses cookies to deliver our services.By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use  Ok, Got it. Close